Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials
An. bras. dermatol
;
92(1): 139-141, Jan.-Feb. 2017. tab
Article
in English
| LILACS
| ID: biblio-1038243
ABSTRACT
ABSTRACT Lamotrigine is an antiepileptic drug used for the treatment of epilepsy, bipolar disorder and numerous off-label uses. The development of rash significantly affects its use. The most concerning of these adverse reactions is Stevens-Johnson syndrome/toxic epidermal necrolysis. We performed a systematic review of randomized controlled trials using lamotrigine as a monotherapy to quantify the incidence of cutaneous reactions, particularly Stevens-Johnson syndrome/toxic epidermal necrolysis. Of a total of 4,364 papers regarding lamotrigine, 122 studies met our inclusion and exclusion criteria. In total, 18,698 patients were included with 1,570 (8.3%) of patients experiencing an adverse dermatologic reaction. The incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis was 0.04%.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Triazines
/
Stevens-Johnson Syndrome
/
Exanthema
/
Anticonvulsants
Type of study:
Controlled clinical trial
/
Incidence study
/
Prognostic study
/
Risk factors
/
Systematic reviews
Limits:
Humans
Language:
English
Journal:
An. bras. dermatol
Journal subject:
Dermatology
Year:
2017
Type:
Article
Affiliation country:
United States
Institution/Affiliation country:
Northshore University Health System/US
/
University of California Irvine/US
Similar
MEDLINE
...
LILACS
LIS